Fractyl Health, Inc. is a metabolic therapeutics company. The company is headquartered in Burlington, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2024-02-02. The firm is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
Follow-Up Questions
¿Quién es el CEO de Fractyl Health Inc?
Dr. Harith Rajagopalan es el Chief Executive Officer de Fractyl Health Inc, se unió a la empresa desde 2011.
¿Qué tal es el rendimiento del precio de la acción GUTS?
El precio actual de GUTS es de $0.9853, ha decreased un 0.32% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Fractyl Health Inc?
Fractyl Health Inc pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de Fractyl Health Inc?
La capitalización bursátil actual de Fractyl Health Inc es $69.7M
¿Es Fractyl Health Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 5 analistas han realizado calificaciones de análisis para Fractyl Health Inc, incluyendo 3 fuerte compra, 5 compra, 1 mantener, 0 venta, y 3 fuerte venta
